IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Snapdragon Chemistry, now part of Cambrex, our chemists specialize in creating custom solutions and technologies to take on your toughest process development and production challenges. This includes expertise in designing and building reactors that enable seamless technology transfer as a process scales up for commercial manufacturing.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex offers a comprehensive suite of testing services for complex biopharmaceuticals including standalone analytical R&D, method validation, release testing, ICH stability, and routine QC testing.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex offers extensive development services tailored to meet your drug product needs in early development. From pre-formulation to Phase II, we ensure your products are developed with speed, flexibility, and quality in mind.
Whether you need rapid development, flexible manufacturing solutions, or high-quality production, Cambrex is your trusted partner for advancing your drug product from concept to the clinic.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
Cambrex’s executive team are seasoned life science professionals with extensive experience leading successful organizations. They provide the vision and strategy that has guided the company through 40 years of transformation — overseeing significant investments in capacity and new capabilities that will further solidify the company’s position as a leading CDMO. Most importantly, they lead by example demonstrating the importance of collaboration and customer service as a clear competitive advantage. Alongside a growing team of more than 2,000 employees, Cambrex leaders partner with customers in their quest to bring novel, life-changing therapies to the market.
Chief Executive Officer
Mr. Loewald joined Cambrex in September 2020 and currently serves as Chief Executive Officer. Mr. Loewald is a 15-year veteran of Thermo Fisher Scientific, where he served in several senior executive roles during his tenure, including Chief Commercial Officer, President of the Analytical Instruments Group, President of the Laboratory Products Group, and President of the Laboratory Equipment and Environmental Instrument Divisions. Earlier in his career, he held leadership positions at Tyco International and General Electric. Mr. Loewald currently serves on the Board of Directors of Harvard BioScience, a global developer, manufacturer, and marketer of a broad range of solutions to advance life science.
Executive Vice President and Chief Financial Officer
Mr. Green joined Cambrex in January 2020 and currently serves as Executive Vice President and Chief Financial Officer. Mr. Green was previously with General Electric Corporation, where he began his career in 1990 and was most recently CFO of GE Power, a global business unit with $35 billion in revenue operating in 180 countries. In his tenure at GE, Robert served as CFO for eight global business units, including as CFO of GE Healthcare Bio-Sciences, a leading medical diagnostic and life sciences products company.
Senior Vice President and General Counsel
Ms. Hanley joined Cambrex in April 2009 and currently serves as Senior Vice President, General Counsel and Corporate Secretary. She previously held the positions of Assistant General Counsel and Assistant Corporate Secretary from January 2013 until February 2015, and Senior Intellectual Property/Corporate Counsel and Assistant Secretary prior to that. Before joining Cambrex, Ms. Hanley worked at Alpharma Pharmaceuticals as Director of Intellectual Property and was an Associate with Lerner, David, Littenberg, Krumholtz & Mentlik, LLP, an intellectual property law firm.
Senior Vice President and Chief Human Resources Officer
Ms. Donnelly-Brienza joined Cambrex in June 2019 and currently serves as Senior Vice President and Chief Human Resources Officer. Previously, Ms. Donnelly-Brienza held the position of Chief Human Resources Officer of Cantel Medical from 2017 to 2019. Prior to that, she held a variety of leadership roles, including almost 20 years at Johnson & Johnson, including CHRO for Ethicon. Ms. Donnelly-Brienza also held senior executive roles at Merck and Bristol-Myers Squibb.
President, Early Stage Development & Testing
Mr. Fincher joined Cambrex in April 2017 and currently serves as President, Early Stage Development and Testing. Mr. Fincher previously served as Chief Strategy Officer at Cambrex, following leadership roles in pharmaceuticals and contract services organizations across multiple disciplines including finance, marketing, strategy, and operations. Prior to that, Mr. Fincher held various positions in engineering, supply chain, and finance at Novartis.
Chief Strategy Officer
Mr. Ferrante joined Cambrex in March 2022 and currently serves as Chief Strategy Officer. Mr. Ferrante previously held the position of Chief Mergers & Acquisitions Officer at Cambrex, following leadership roles in M&A and business development at Quest Diagnostics and Corporate Development at Thermo Fisher Scientific. Prior to that, Mr. Ferrante held roles of increasing responsibility in management consulting at Bain & Company.
Chief Operating Officer, Drug Substance
Mr. Russolo joined Cambrex in 2002 and currently serves as Chief Operating Officer, Drug Substance. He previously held the roles of President, Generic Drug Substance Business Unit, VP Sales & Marketing, Marketing & Sales Director, and Area Manager for Cambrex Profarmaco Milano. Prior to joining the company, Mr. Russolo held roles at the Cambrex-owned corporations of Conti B.P.C. and Seal Sands Chemicals.
Chief Scientific Officer & President, Snapdragon Chemistry
Dr. Bio joined Cambrex in 2023 and currently serves as Chief Scientific Officer, Cambrex and President, Snapdragon Chemistry (a Cambrex Company). Prior to serving as President & CEO of Snapdragon, Dr. Bio held roles at Amgen Inc. and Merck Research Laboratories. He is a member of the American Chemical Society and the American Association for the Advancement of Science and has published extensively on the topic of process development. He holds multiple patents and is a reviewer for several scientific journals.